Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 20/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 20/20 | 0.63 |
| ▸ | PTPN5 | P54829 | 20/20 | 0.63 |
| ▸ | HSPD1 | P10809 | 7/20 | 0.57 |
| ▸ | HSPE1 | P61604 | 7/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084264 | 0.90 | PTPN2 (0.66) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL6084255 | 0.90 | PTPN2 (0.58) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL6086234 | 0.88 | PTPN5 (0.74) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL6202999 | 0.88 | PTPN2 (0.60) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL6084787 | 0.87 | PTPN1 (0.44) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL6085852 | 0.86 | PTPN5 (0.49) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL6086154 | 0.84 | PTPN5 (0.60) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL6085283 | 0.82 | PTPN1 (0.61) | PTPN2PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL6084937 | 0.81 | CETP (0.49) | — | |
| SCHEMBL6085199 | 0.80 | PTPN1 (0.61) | PTPN2PTPN1PTPN5HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | claimed |
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | disclosed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | disclosed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | MAP3K15, MAP3K20, MAP3K3 | PTPN2 370/4885PTPN1 344/4885PTPN5 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.